CBAY
- · NASDAQ
- Sector -
- Industry -
- Website cymabay.com
- Employees(FY) 60
- ISIN -
Performance
-
1W
-
1M
-
3M
+0.74%
6M
+37.51%
YTD
+134.85%
1Y
Profile
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of autoimmune liver disease, primary biliary cholangitis (PBC). The company also develops MBX-2982 for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.
Recent News & Updates
- 2024-03-22 09:18
- 2024-03-21 21:18
- 2024-03-11 14:23
- 2024-03-04 08:00
- 2024-03-03 19:00
- 2024-02-28 18:10
- 2024-02-28 16:45
- 2024-02-28 03:45
- 2024-02-21 17:43
- 2024-02-21 04:43
- 2024-02-20 16:05
- 2024-02-20 03:05
- 2024-02-15 08:28
- 2024-02-15 03:01
- 2024-02-13 09:24
- 2024-02-12 12:34
Trimble, CymaBay Therapy rise; Big Lots, Monday.com fall, Monday, 2/12/2024(Associated Press Finance)
- 2024-02-12 12:27
Stocks to Watch Monday: Diamondback, CymaBay, Gilead, Tod's(The Wall Street Journal)
- 2024-02-12 12:03
Why Wall Street Was Lukewarm on Gilead’s $4.3 Billion Liver-Drug Deal(The Wall Street Journal)
- 2024-02-12 10:57
CymaBay Rockets After Gilead Snaps Up The Liver-Focused Biotech For $4.3 Billion(Investor's Business Daily)
- 2024-02-12 09:57
- 2024-02-12 09:45
CymaBay Therapeutics Shares Hit All-Time High on Gilead Deal(The Wall Street Journal)
- 2024-02-12 08:45
- 2024-02-12 08:42
- 2024-02-12 08:38
- 2024-02-12 08:33
- 2024-02-12 00:43
- 2024-02-12 00:27
- 2024-02-11 20:18
- 2024-02-11 19:45
- 2024-02-11 19:44
Gilead Sciences to Buy CymaBay Therapeutics for $4.3 Billion(Yahoo Finance)
Page 1 of 5
previousnext
Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.